Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that research involving its SNAP-CAR technology was detailed in a peer-reviewed article published in the peer-reviewed journal, Nature Communications.
SNAP-CAR represents a major advance potentially expanding the targeting capabilities of chimeric antigen receptor (CAR) T cells for various cancers and other indications WEXFORD, Pa., May 10, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that research involving its SNAP-CAR technology was detailed in a peer-reviewed article published in the peer-reviewed journal, Nature Communications. SNAP-CAR is a multi-antigen chimeric antigen receptor T cell (CAR T) technology that can be adapted to different cancer indications, including hematologic and solid tumors. The article titled, "Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting," describes key advances in antigen receptor design to develop "universal" receptor systems for diverse programming of cell behaviors using covalent chemistry. Using in vitro and in vivo models, the authors demonstrated that the SNAP-CAR platform provides a powerful adaptor strategy for fully programmable targeting of engineered cells to multiple antigens. Further, it was concluded that these systems have the potential for clinical application and biotechnological utility by providing researchers with the ability to rapidly screen CAR and synNotch antibody candidates and to rewire and activate cellular programs in response to highly specific antibody-antigen interactions. "This research highlights key advances in antigen receptor design, including the creation of a universal adaptor synNotch system and a universal CAR system that act through self-labeling enzyme chemistry, representing a potential breakthrough in programmable antigen targeting," said Jason Lohmueller, Ph.D., Assistant Professor of Surgery and Immunology in the Division of Surgical Oncology Research, University of Pittsburgh. "These 'universal' receptor systems, for which receptor specificity can be directed post-translationally via covalent attachment of a co-administered antibody, offer the potential to allow for one population of T cells to target multiple tumor antigens, enabling the development of cell therapies for a wide range of cancers, including hematologic and solid tumors." "SNAP-CAR represents a powerful technology with the potential to be engineered to address numerous cancers, including HER2-expressing cancer, which we are targeting as our potential first-in-human clinical development program," said Dave Mehalick, President and CEO of Coeptis Therapeutics. "Having research on SNAP-CAR published in such a prestigious scientific journal as Nature Communications provides further validation of the technology's potential and the groundbreaking work being conducted by Dr. Lohmueller and his team at the University of Pittsburgh." About SNAP-CAR About Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by assets from Deverra Therapeutics including an allogeneic stem cell platform and DVX201, an unmodified natural killer (NK) cell therapy in Phase 1 clinical trials, a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and intellectual property and knowhow related the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/. Cautionary Note Regarding Forward-Looking Statements CONTACTS Coeptis Therapeutics, Inc. Tiberend Strategic Advisors, Inc. Media SOURCE Coeptis |
||
Company Codes: NASDAQ-NMS:COEP |